5/31/2013

GE Healthcare said findings from three studies of its DaTscan tracer and imaging agent flutemetamol will be discussed at the SNMMI Annual Meeting. Two of the studies focused on DaTscan applications for Parkinsonian syndromes. The third study compares 18F-flutemetamol quantification results with histopathology findings.

Related Summaries